1. Електронний репозитарій ДВНЗ "УжНУ"

Перегляд зібрання за групою - Автори Yevhen Hotko

Перейти до: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
або ж введіть декілька перших літер:  
Результати 1 до 5 із 5
Дата випускуНазваАвтор(и)
2013A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES StudyTamás Pintera; Zandra Klippel; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Kurteva; Jan Novotny; Seamus O’Reilly; Tomas Salek; Maureen Reiner; Phuong Khanh Morrow; Mi Rim Choi; Sadie Whittaker; Charles Blanke
2015Analysis of KRAS/NRAS Mutations in a Phase 3 Study of Panitumumab With FOLFIRI Compared With FOLFIRI Alone as Second-Line Treatment for Metastatic Colorectal CancerMarc Peeters; Kelly S. Oliner; Timothy Jay Price; Andres Cervantes; Alberto F. Sobrero; Michel Ducreux; Yevhen Hotko; Thierry Andre; Emily Chan; Florian Lordick; Cornelis J. A. Punt; Andrew Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Ying Tian; Andre Scott Jung; Roger Sidhu; Scott D. Patterson
2012Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC)Alberto F. Sobrero; Marc Peeters; Timothy Jay Price; Yevhen Hotko; Andres Cervantes-Ruiperez; Michel Ducreux; Thierry Andre; Emily Chan; Florian Lordick; Ying Tian; Roger Sidhu
2013Resultsof a phase III, randomized, double-blind, placebocontrolledtrialofpegfilgrastim (PEG) inpatients (pts) receivingfirst-line FOLFOX or FOLFIRI andbevacizumab (B) forcolorectalcancer (CRC)Tamas Pinter; Esteban Abella; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Petrova Kurteva; Jan Novotny; Seamus O'Reilly; Tomas Salek; May F. Mo; L. MiRim Choiand Charles Davic Blanke
2014-05-20Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).Marc Peeters; Kelly Smith Oliner; Timothy Jay Price; Andres Cervantes; Alberto F. Sobrero; Michel Ducreux; Yevhen Hotko; Thierry Andre; Emily Chan; Florian Lordick; Cornelis JA Punt; Andrew Strickland; Gregory Wilson; Tudor E Ciuleanu
Результати 1 до 5 із 5